# Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine

> **NCT00103467** · PHASE1 · COMPLETED · sponsor: **VaxGen** · enrollment: 100 (—)

## Conditions studied

- Prevention of Anthrax Infection

## Interventions

- **BIOLOGICAL:** rPA102 Vaccine

## Key facts

- **NCT ID:** NCT00103467
- **Lead sponsor:** VaxGen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 100 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00103467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00103467, "Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00103467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*